SEARCH

SEARCH BY CITATION

References

  • 1
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 17331745.
  • 2
    Lai CL, Ratziu V, Yuen MF, Paynard T. Viral hepatitis B. Lancet 2003; 362: 20892094.
  • 3
    Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 13561361.
  • 4
    Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastoenterol Hepatol 1997; 12: S294S298.
  • 5
    Chen CJ, Yang HI, Jun S, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 6
    Liaw YF, Sung JJY, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 15211531.
  • 7
    Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173184.
  • 8
    Yokosuka O, Takaguchi K., Fujioka S, Shindo M, Chayama K, Kobashi H, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010; 52: 791799.
  • 9
    Chang TT, Lai CL, Yoon SK, Lee SS, Coelho HSM, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. HEPATOLOGY 2010; 51: 422430.
  • 10
    Yang HI, Yuen MF, Chan HLY, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568574.
  • 11
    Yuen MF, Tanaka Y, Fong DYT, Fung J, Wong DKH, Yuen JCH, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 8088.
  • 12
    Wong VWS, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 16601665.
  • 13
    Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010; 28: 24372444.
  • 14
    Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516524.
  • 15
    Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002; 137: 693695.
  • 16
    Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. J Am Stat Assoc 1985; 39: 3338.
  • 17
    D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 22652281.
  • 18
    Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 11411154.
  • 19
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496509.
  • 20
    Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930938.
  • 21
    Kato Y, Nakata K, Omagari K, Furukawa R, Kusumoto Y, Mori I, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Cancer 1994; 74: 22342238.
  • 22
    Lo KJ, Tong MJ, Chien MC, Tsai YT, Liaw YF, Yang KC, et al. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J Infect Dis 1982; 146: 205210.
  • 23
    Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2022; 347: 168174.
  • 24
    Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554559.
  • 25
    Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. HEPATOLOGY 2009; 49: S72S84.
  • 26
    Zhang Q-Q, An X, Liu YH, Li SY, Zhong Q, Wang J, et al. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J 2011; 8: 72.
  • 27
    Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348356.
  • 28
    Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastoenterology 2011; 141: 12401248.
  • 29
    Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, et al. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012; 47: 577585.